Ignite Creation Date:
2024-05-06 @ 4:11 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04896697
Status:
RECRUITING
Last Update Posted:
2023-08-25
First Post:
2021-05-06
Brief Title:
Vilastobart XTX101 Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Sponsor:
Xilio Development Inc
Organization:
Xilio Development Inc
Organization Data
Organization:
Xilio Development Inc
Class:
INDUSTRY
Study ID:
XTX101-0102-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Xilio Development Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |